Brought to you by:
‘This is just the beginning’: SVS launches patient-facing website in opening salvo of long-term branding campaign
The Society for Vascular Surgery (SVS) has launched a new patient-facing website aimed at bridging the information gap between members of the public and their vascular care providers. Your Vascular Health allows patients to navigate the complexities of vascular health…
VASC.AI: Canadian vascular surgery researchers develop vascular-specific bot aimed at aiding education and clinical practice
The advent of large language models such as ChatGPT (Open AI) has left little of the world untouched—and a quintet of University of Toronto vascular surgery researchers are bidding to harness this mode of artificial intelligence (AI) and refine it…
Service: Giving back
Pioneering American Venous Forum (AVF) and Eastern Vascular Society (EVS) efforts aimed at breaking down barriers to care and educating patients in economically challenged communities on vascular disease have yielded early gains over the first two events staged this year.…
Novel measure suggests 20% of elective carotid revascularizations fail to achieve a textbook outcome
One in five patients failed to achieve a textbook outcome after undergoing carotid endarterectomy (CEA), transcarotid artery revascularization (TCAR) or transfemoral carotid artery stenting (TF-CAS), a Vascular Quality Initiative (VQI) analysis that tested a novel, patient-centric textbook outcome metric found.…
Bentley announces first-in-human implantation of BeFlared bridging stent
Bentley has announced the successful first-in-human implantation of its recently CE-certified BeFlared stent graft system, which the company states is the world’s first dedicated bridging stent for fenestrated endovascular aneurysm repair (FEVAR). The procedure was performed by Stéphan Haulon, MD,…
WAVE trial AVG cohort also benefits at six months with Wrapsody
Newly released six-month results from single-arm arteriovenous graft (AVG) cohort in the WAVE (Wrapsody arteriovenous access efficacy) trial showed target lesion and access circuit primary patency rates of nearly 82% and 68.8%, respectively. The latest data on the Wrapsody cell-permeable…
BEST-CLI: Trial results endure in analysis of patients who presented with diabetes
Diabetes affects approximately 70% of patients with chronic limb-threatening ischemia (CLTI) and is associated with more severe presentation, driven mostly by higher rates of wounds and infections, according to a recently presented retrospective analysis of BEST-CLI randomized controlled trial data.…
Rates of MAE and reintervention following F/BEVAR remain ‘stable,’ Aortic Research Consortium data show
Latest study out of consortium details trends and outcomes after F/BEVAR procedures carried out over an eight-year period under consortium of 10 physician-sponsored IDEs. Despite increasing repair extent and complexity, rates of technical failure, adverse events and reintervention remained “stable”…
Humacyte clinical results published in JAMA Surgery
Humacyte today announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel (ATEV) in the repair of extremity civilian and military injuries in JAMA Surgery, an American Medical Association peer-reviewed journal. The publication…
One-year data from VenoValve US pivotal trial emerges
Envveno Medical has announced that it will present one-year data on all patients from the VenoValve US pivotal trial today at the VEITHsymposium (19–23 November, New York, USA). The definitive one-year data support the application submitted earlier this week by Envveno Medical seeking…